Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer
Open Access
- 13 February 2008
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 19 (3), 596-597
- https://doi.org/10.1093/annonc/mdn021
Abstract
HER2/neu oncogene overexpression has become a paramount prognostic and predictive marker in invasive breast carcinoma [1]. Its expression is usually highly homogeneous in malignant tissue [2]. Some cases of intratumoral heterogeneity have, however, been reported [3] (Figure 1). The impact of this heterogeneity on the natural history of breast cancer and its consequences on clinical management are unknown. We report here three clinical cases illustrating the complexity of this topic.This publication has 7 references indexed in Scilit:
- Trastuzumab — Mechanism of Action and Use in Clinical PracticeThe New England Journal of Medicine, 2007
- Intratumoral Heterogeneity of HER2/neu in Breast Cancer?A Rare EventThe Breast Journal, 2007
- Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?Journal of Clinical Oncology, 2007
- A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized Anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxelHuman Pathology, 2004
- Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* StudyHistopathology, 2003
- Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sitesAnnals of Oncology, 2002
- HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer, 2002